Search results for " dose"

showing 10 items of 593 documents

A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Re…

2006

Clinical studies have demonstrated beneficial effects for clopidogrel in patients with atherothrombotic disease. Recent in vitro studies identified stimulating effects of clopidogrel on endothelial cells, pointing towards mechanisms of action beyond the inhibition of platelet aggregation. We hypothesized that in vivo use of clopidogrel improves endothelial dysfunction in patients with coronary artery disease (CAD). Fifty-eight patients with CAD were randomly assigned to double-blinded oral administration of one single dose of clopidogrel 300 mg (C300) or 600 mg (C600), respectively. Endothelial function was assessed by measurement of flow-mediated dilation (FMD) of the brachial artery befor…

Blood PlateletsMalemedicine.medical_specialtyTiclopidineCoronary Artery DiseaseLoading doseCoronary artery diseaseP2Y12Double-Blind MethodSuperoxidesmedicine.arteryInternal medicinePurinergic P2 Receptor AntagonistsHumansMedicinePlateletcardiovascular diseasesBrachial arteryEndothelial dysfunctionAgedbusiness.industryVascular diseaseMicrofilament ProteinsMiddle AgedPhosphoproteinsmedicine.diseaseClopidogrelReceptors Purinergic P2Y12ClopidogrelAnesthesiaCardiologyFemaleEndothelium VascularCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesDilatation Pathologiccirculatory and respiratory physiologymedicine.drugAtherosclerosis
researchProduct

Body composition characteristics and body surface area

2013

Chemotherapy dose calculation for oncologycal patient is using the human body surface area (BSA). BSA is a variable with a difficult constitutional body and physiological assessment. BSA does not reflect the exercise on body composition in relation to the various body modifications: obesity, amputation of body parts, pregnancy. Body surface area despite the documented limitations remains the most commonly used parameter chemotherapy (cytotoxic therapy) of cancer patients. The new guidelines are intended obese patients is to achieve the same maximum dose rate calculated BSA taking into account the full weight rather than using the statement or reduce weight by restricting intake. Experience …

Body surface areaPregnancymedicine.medical_specialtyChemotherapyDose calculationbusiness.industrymedicine.medical_treatmentPhysiologymedicine.diseaseObesitySurgeryAmputationMaximum dosemedicineCytotoxic TherapybusinessPapers on Anthropology
researchProduct

The alanine detector in BNCT dosimetry: Dose response in thermal and epithermal neutron fields

2014

Purpose: The response of alanine solid state dosimeters to ionizing radiation strongly depends on particle type and energy. Due to nuclear interactions, neutron fields usually also consist of secondary particles such as photons and protons of diverse energies. Various experiments have been carried out in three different neutron beams to explore the alanine dose response behavior and to validate model predictions. Additionally, application in medical neutron fields for boron neutron capture therapy is discussed. Methods: Alanine detectors have been irradiated in the thermal neutron field of the research reactor TRIGA Mainz, Germany, in five experimental conditions, generating different secon…

Bonner sphereMaterials sciencebusiness.industryPhysics::Medical Physicstechnology industry and agricultureGeneral MedicineNeutron temperatureNuclear physicsNeutron captureAbsorbed doseNeutron cross sectionDosimetryNeutron sourceNeutronNuclear medicinebusinessMedical Physics
researchProduct

Changes in selected biochemical parameters in the brain of the fish, Anguilla anguilla (L.), exposed to lindane.

1991

Brain ChemistryHealth Toxicology and MutagenesisZoologyGeneral MedicineBiologyToxicologyAnguillaLipid MetabolismPollutionToxicologyLethal Dose 50chemistry.chemical_compoundchemistryFresh waterToxicityLactatesFish <Actinopterygii>EcotoxicologyAnimalsLindanePyruvatesGlycogenHexachlorocyclohexaneBulletin of environmental contamination and toxicology
researchProduct

Cumulative radiation CT dose in non-oncological patients : a single centre 5 years retrospective review

2013

CT dose cumulative
researchProduct

Comparing the acute response to cadmium toxicity of nauplii from different populations ofArtemia

2002

The lethal responses to cadmium of instar II nauplii from eight populations of Artemia belonging to the species Artemia franciscana, Artemia salina, Artemia persimilis, and Artemia parthenogenetica have been compared. Generalized linear models were used to fit mortality. The model indicates that there is a relationship between species, type of population, and mortality rate. The two populations of A. franciscana were the most sensitive to cadmium toxicity (median lethal concentration, LC50, of 93.3-142 mg/L), while the population of A. persimilis was the most resistant (LC50 of 284 mg/L). Differences in the phenotypic variability in each population were assessed through the slope of the mor…

Cadmiumeducation.field_of_studybiologyEcologyHealth Toxicology and MutagenesisPopulationArtemia parthenogeneticachemistry.chemical_elementZoologyBranchiopodabiology.organism_classificationMedian lethal doseAcute toxicitychemistryEnvironmental ChemistryInstarArtemia salinaeducationEnvironmental Toxicology and Chemistry
researchProduct

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

2015

Goodson, William H. et al.

Cancer ResearchCarcinogenesis[SDV]Life Sciences [q-bio]METHOXYCHLOR-INDUCED ALTERATIONSReviewPharmacologyMESH: Carcinogens EnvironmentalCarcinogenic synergiesChemical mixturesNeoplasmsMESH: AnimalsMESH: NeoplasmsCarcinogenesiRisk assessmentCancerACTIVATED PROTEIN-KINASESMedicine (all)Low dose1. No povertyCumulative effectsBREAST-CANCER CELLSGeneral MedicineEnvironmental exposureMESH: CarcinogenesisBIO/10 - BIOCHIMICAEPITHELIAL-MESENCHYMAL TRANSITION3. Good health[SDV] Life Sciences [q-bio]Environmental CarcinogenesisESTROGEN-RECEPTOR-ALPHARisk assessmentHumanMESH: Environmental ExposureENDOCRINE-DISRUPTING CHEMICALSTARGETING TISSUE FACTOR[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPrototypical chemical disruptorsExposure[SDV.CAN] Life Sciences [q-bio]/CancerEnvironmental healthmedicine[SDV.EE.SANT] Life Sciences [q-bio]/Ecology environment/HealthCarcinogenEnvironmental carcinogenesis[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthMESH: HumansAnimalPOLYBROMINATED DIPHENYL ETHERSCancerEnvironmental Exposuremedicine.diseaseMESH: Hazardous SubstancesCarcinogens EnvironmentalMIGRATION INHIBITORY FACTORVASCULAR ENDOTHELIAL-CELLSHazardous SubstanceNeoplasmCarcinogenesis
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

Influence of Mitoxantrone on the Syntheses of Dna and Proteins of Mouse Tissues

1991

In view of the structural similarity of mitoxantrone to anthracyclines and its ability to intercalate into DNA, we studied its influence on the synthetic processes of DNA and proteins in CD-1 mice tissues. By studying at the DNA level the impairment of 2H-thymidine incorporation and its return to normal, it was found that bone marrow and spleen showed similar behavior, i.e., a rapid return to normal, which occurred before bone marrow cell number and spleen weight returned to basal values. At the cardiac level, the incorporation values of precursors into DNA, reduced by treatment with mitoxantrone, came back very slowly to the control ones. Hepatic DNA showed a lower sensitivity to mitoxant…

Cancer ResearchStructural similarityMuscle ProteinsSpleen030218 nuclear medicine & medical imagingMice03 medical and health sciencesBasal (phylogenetics)chemistry.chemical_compound0302 clinical medicineBone MarrowmedicineAnimalsDoxorubicinMitoxantroneCumulative doseChemistryMyocardiumHeartDNAGeneral MedicineMolecular biologymedicine.anatomical_structureLiverOncology030220 oncology & carcinogenesisBone marrowMitoxantroneSpleenDNAmedicine.drugTumori Journal
researchProduct

Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone recep…

2021

Abstract Background GDC-0077 is a PI3Kα-selective inhibitor and mutant PI3Kα degrader that demonstrates antitumor activity in PIK3CAmut BC xenograft models. A phase I/Ib study of GDC-0077 alone and combined with endocrine therapy ± the CDK4/6 inhibitor (i) palbo is ongoing (NCT03006172). Data from GDC-0077 + palbo + fulvestrant in pts with PIK3CAmut, HR+/HER2- mBC are presented herein. Methods Safety (NCI-CTCAE v4), pharmacokinetics (PK), and preliminary antitumor activity (clinical benefit rate [CBR]: RECIST v1.1 stable disease for ≥ 24 weeks, partial response [PR], or complete response) of 9 mg oral once daily GDC-0077 + 125 mg palbo 21/28 days + 500 mg intramuscular fulvestrant on day 1 …

Cancer Researchmedicine.medical_specialtyChemotherapyFulvestrantNauseaCumulative dosebusiness.industrymedicine.medical_treatmentNeutropeniaPalbociclibmedicine.diseaseGastroenterologyMetastatic breast cancerBreast cancerOncologyInternal medicinemedicinemedicine.symptombusinessmedicine.drugCancer Research
researchProduct